ESTERIFIED ESTROGENS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ESTERIFIED ESTROGENS (ESTERIFIED ESTROGENS).

How it works

Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, promoting proliferation of endometrial and breast epithelium, and exerting effects on bone, cardiovascular, and central nervous systems.

What the body does with it

Metabolism	Hepatic metabolism via CYP3A4 and other CYP450 enzymes; undergoes enterohepatic recirculation; conjugated as glucuronides and sulfates.
Excretion	Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Approximately 60-80% of the dose is excreted in the urine (as glucuronide and sulfate conjugates), with the remaining 20-40% excreted in feces via bile.
Half-life	Terminal elimination half-life is approximately 10-24 hours, reflecting the prolonged activity of conjugated metabolites and enterohepatic cycling. Steady-state is achieved within 3-5 days.
Protein binding	Esterified estrogens are approximately 50-80% bound to serum albumin and sex hormone-binding globulin (SHBG). Binding is reversible and saturable.
Volume of Distribution	Apparent volume of distribution is estimated at 0.5–1.0 L/kg, indicating distribution into total body water and some tissue binding. Large Vd reflects extensive tissue uptake, especially in adipose tissue.
Bioavailability	Oral: bioavailability of esterified estrogens is approximately 30-50% due to extensive first-pass hepatic metabolism. Micronized formulations may yield higher bioavailability (up to 50-60%).
Onset of Action	Oral: clinical effects on vasomotor symptoms (hot flushes) typically begin within 2-4 weeks. Topical (vaginal cream): local effects on urogenital epithelium may occur within a few days.
Duration of Action	After discontinuation, estrogenic effects persist for several days to 1 week due to enterohepatic recirculation and tissue storage. Maximal effect on menopause symptoms may last 24-48 hours post-dose, but duration depends on individual metabolism and dose.

Classification & Brands

Dosing & administration

1.25 mg orally once daily for 21 days, followed by a 7-day drug-free period per cycle. Adjust based on response.

Dosage form	TABLET
Renal impairment	No specific dose adjustment guidelines; use with caution in severe renal impairment (eGFR <30 mL/min).
Liver impairment	Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), initiate at lowest effective dose and monitor liver function.
Pediatric use	Not indicated for use in pediatric patients; safety and efficacy not established.
Geriatric use	Initiate at low dose (0.3-0.625 mg daily) with gradual titration; monitor for thromboembolic events, cardiovascular risks, and endometrial hyperplasia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ESTERIFIED ESTROGENS (ESTERIFIED ESTROGENS).

Breastfeeding	Esterified estrogens are excreted in human milk in low concentrations; M/P ratio not established. Breastfeeding is generally contraindicated due to potential suppression of lactation and estrogenic effects on infant. Alternative therapies should be considered.
Teratogenic Risk	First trimester: Increased risk of congenital anomalies including cardiac defects and neural tube defects; second and third trimesters: Potential for feminization of male fetus, urogenital tract abnormalities, and functional impairment of reproductive organs. Estrogenic effects on fetal development are dose-dependent and duration-dependent.

Warnings & precautions

■ FDA Black Box Warning

Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer in women with intact uterus. Increased risk of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Increased risk of probable dementia in postmenopausal women aged 65 years or older.

Side Effect Profile

Serious Effects

Absolute Contraindications

Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history thereof (unless on anticoagulant therapy), active arterial thromboembolic disease (e.g., stroke, MI) or history thereof, known liver dysfunction or disease, known hypersensitivity to estrogens.

Clinical Precautions

Precautions

Cardiovascular disorders (stroke, MI, DVT, PE), malignancy (endometrial, breast, ovarian), dementia, gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, visual abnormalities, exacerbation of endometriosis, and use with caution in patients with liver impairment, porphyria, or thyroid disorders.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ESTERIFIED ESTROGENS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ESTERIFIED ESTROGENS (ESTERIFIED ESTROGENS).

How it works

What the body does with it

Metabolism	Hepatic metabolism via CYP3A4 and other CYP450 enzymes; undergoes enterohepatic recirculation; conjugated as glucuronides and sulfates.
Excretion	Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Approximately 60-80% of the dose is excreted in the urine (as glucuronide and sulfate conjugates), with the remaining 20-40% excreted in feces via bile.
Half-life	Terminal elimination half-life is approximately 10-24 hours, reflecting the prolonged activity of conjugated metabolites and enterohepatic cycling. Steady-state is achieved within 3-5 days.
Protein binding	Esterified estrogens are approximately 50-80% bound to serum albumin and sex hormone-binding globulin (SHBG). Binding is reversible and saturable.
Volume of Distribution	Apparent volume of distribution is estimated at 0.5–1.0 L/kg, indicating distribution into total body water and some tissue binding. Large Vd reflects extensive tissue uptake, especially in adipose tissue.
Bioavailability	Oral: bioavailability of esterified estrogens is approximately 30-50% due to extensive first-pass hepatic metabolism. Micronized formulations may yield higher bioavailability (up to 50-60%).
Onset of Action	Oral: clinical effects on vasomotor symptoms (hot flushes) typically begin within 2-4 weeks. Topical (vaginal cream): local effects on urogenital epithelium may occur within a few days.
Duration of Action	After discontinuation, estrogenic effects persist for several days to 1 week due to enterohepatic recirculation and tissue storage. Maximal effect on menopause symptoms may last 24-48 hours post-dose, but duration depends on individual metabolism and dose.

Classification & Brands

Dosing & administration

1.25 mg orally once daily for 21 days, followed by a 7-day drug-free period per cycle. Adjust based on response.

Dosage form	TABLET
Renal impairment	No specific dose adjustment guidelines; use with caution in severe renal impairment (eGFR <30 mL/min).
Liver impairment	Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), initiate at lowest effective dose and monitor liver function.
Pediatric use	Not indicated for use in pediatric patients; safety and efficacy not established.
Geriatric use	Initiate at low dose (0.3-0.625 mg daily) with gradual titration; monitor for thromboembolic events, cardiovascular risks, and endometrial hyperplasia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ESTERIFIED ESTROGENS (ESTERIFIED ESTROGENS).

Breastfeeding	Esterified estrogens are excreted in human milk in low concentrations; M/P ratio not established. Breastfeeding is generally contraindicated due to potential suppression of lactation and estrogenic effects on infant. Alternative therapies should be considered.
Teratogenic Risk	First trimester: Increased risk of congenital anomalies including cardiac defects and neural tube defects; second and third trimesters: Potential for feminization of male fetus, urogenital tract abnormalities, and functional impairment of reproductive organs. Estrogenic effects on fetal development are dose-dependent and duration-dependent.